Indications for: LEQVIO
Adjunct to diet and statin therapy in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C.
Give by SC inj into abdomen, thigh, or upper arm. Initially 284mg as a single inj, repeat at 3 months, and then every 6 months. Measure LDL-lowering effect as early as 30 days after initiation and anytime thereafter.
Do not inject into areas of active skin disease or injury (eg, sunburns, skin rashes, inflammation, skin infections). ESRD. Severe hepatic impairment. Pregnancy: avoid. Nursing mothers.
Small interfering RNA (siRNA).
Inj site reaction, arthralgia, bronchitis.
Renal (~16%). Half-life: ~9 hours.
Generic Drug Availability:
Single-dose prefilled syringe—1